JTO: Relationship between aspirin, statins and metformin and lung cancer risk and associated mortality.

The purpose of this study was to study the relationship between aspirin, metformin and statins and lung cancer risk and mortality using population-based national queue data.
study included 732,199 participants who received national health checks in 2002-2003.
use the registered lung cancer diagnostic code (ICD-10 code C34) and the Korea National Death Registry to determine the incidence and mortality of lung cancer.
follow-up of study participants from 1 January 2004 to 31 December 2013.
of the drug is defined by the daily dose (cDDD) defined by cumulative use time and accumulation every 2 years interval.
to avoid time bias, drug exposure was evaluated as a time-dependent variable in Cox analysis, which assessed the association between these drugs and lung cancer.
the use of metformin was associated with a dose response relationship with the incidence of lung cancer (trend P s 0.008) and mortality (trend P slt;0.001), and these associations were particularly pronounced in participants with metformin cdDDD≥ .
, these relationships were significantly more pronounced among participants ≥ metformin cdDDD and 547.5 participants.
use of aspirin (P, 0.046) and statins (P ,lt;0.001) can reduce lung cancer mortality.
combined use of aspirin, statins and metformin has a more significant protective effect on lung cancer risk and mortality.
aspirin, the use of metformin and statins was independently protectively associated with lung cancer mortality, and metformin was negatively associated with the risk of lung cancer.
further research is needed to develop clinically applicable anti-cancer strategies for these drugs to reduce lung cancer and related mortality.
.